Truxima (rituximab-abbs; Teva and Celltrion), a biosimilar to Rituxan (rituximab; Genentech) will be available in the US the week of November 11, 2019 for the treatment of adults with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Specifically, Truxima is indicated for:
- Relapsed or refractory, low grade or follicular, CD20-positive, B-cell NHL as a single agent;
- Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy
- Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine and prednisone chemotherapy
- Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) or other anthracycline-based chemotherapy regimens
- Treatment of adult patients with previously untreated and previously treated CD20-positive CLL, in combination with fludarabine and cyclophosphamide
Truxima is supplied as a preservative-free solution for intravenous (IV) infusion as 100mg/10mL or 500mg/50mL single-dose vials. The wholesale acquisition cost of the biosimilar will be 10% lower than the reference product. In addition, the Comprehensive Oncology Reimbursement Expertise (CORE) program from Teva will be available to patients, caregivers, and healthcare professionals to help with the reimbursement process and provide patient assistance, including a savings program for eligible patients.
For more information visit truximahcp.com.
This article originally appeared on MPR